

# Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases



- \$46M in Financing Secured from leading global life science investors
  - Frederick Beddingfield Appointed as CEO
- 

NEWS PROVIDED BY  
**Kira Pharmaceuticals** →  
Nov 12, 2020, 07:00 ET

---

CAMBRIDGE, Md. and SUZHOU, China, Nov. 12, 2020 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced \$46M in investments secured to date and the appointment of Frederick Beddingfield, MD, PhD as Chief Executive Officer. Kira is backed by a syndicate of leading global life science venture firms including Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital and plans to rapidly advance a pipeline of novel therapies designed to achieve better, longer lasting immune modulation.

"Kira has developed a scientifically innovative platform technology and a breakthrough approach to developing transformative therapies for patients with complement-mediated diseases," said Peter Wirth, senior advisor and board member of Kira Pharmaceuticals and Venture Partner at the lead investor Quan Capital. "We are pleased to welcome

Frederick at a critical time for the organization. His experience and expertise in building and guiding research organizations will be invaluable as Kira prepares to advance a robust pipeline of complement targeted therapies to the clinic."

"Kira's founding team has developed an intelligent drug discovery platform driving the development of novel compounds with the ability to overcome the challenges of complement drug discovery and modulate the complement system in new and thoughtful ways," said Dr. Beddingfield, CEO, Kira Pharmaceuticals. "I am honored and excited to join Kira on its mission to advance several first-in-class therapies for the benefit of patients in desperate need of treatment options."

With a therapeutic focus on inflammatory and autoimmune diseases and oncology, Kira has plans to advance three complement-targeted therapies to the clinic over the next 18 months. Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets. By regulating two separate rate-limiting steps in the complement activation cascade that are critical for disease development, P014 provides a powerful, and potentially safer approach to complement inhibition. P014 has also been engineered with an extended half-life and potency, with the opportunity for self-administration at home.

Founded by some of the foremost experts in complement biology, Kira Pharmaceuticals has designed its LOGIC drug discovery platform (**L**ead identification, **O**ptimization and attribute **G**eneration, **I**n vivo **C**onfirmation) to overcome the challenges of complement drug discovery. The complement system is a key driver and amplifier of inflammation and tissue damage in many human diseases but is complex and historically difficult to target.

"This drug discovery platform is based on technology and animal models licensed from the University of Pennsylvania and I am very pleased to see this effort to translate our research findings into medicine for patients in need," said Wenchao Song, PhD, scientific co-founder and Chair of the Scientific Advisory Board of Kira Pharmaceuticals. Song is also a professor of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine at University of Pennsylvania.

Dr. Beddingfield joins Kira with nearly 20 years of biopharma experience. Beddingfield will lead Kira as the company moves quickly to expand the impact of its LOGIC platform while advancing a portfolio of complement-targeted therapies into the clinic. Most recently, Dr. Beddingfield was founder and CEO of Sienna Biopharmaceuticals, a company developing topical and systemic therapies for inflammatory and immune-mediated skin diseases. Prior to Sienna, he served as Chief Medical Officer at both Kythera and Allergan Medical. Dr. Beddingfield is board certified in Dermatology, Mohs Micrographic Surgery, Cutaneous Oncology and Emergency Medicine. He is also an Associate Clinical Professor at UCLA. Dr. Beddingfield received his MD from the University of North Carolina (UNC)-Chapel Hill and PhD from Pardee RAND Graduate School.

### **About Kira Pharmaceuticals**

Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. Enabled by its LOGIC drug discovery platform, the company is committed to advancing first-in-class and best-in-class therapies to transform the lives of patients with complement-driven diseases. With offices in Cambridge, Massachusetts and an R&D center in Suzhou, China, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies to patients around the world.

For more information, please visit [www.kirapharma.com](http://www.kirapharma.com).

SOURCE Kira Pharmaceuticals

### Related Links

<http://www.kirapharma.com>

科越新闻稿

起草日期：2020 年 10 月 19 日

## 科越医药率先推出治疗补体介导疾病的创新疗法

- 已获得全球领先的生命科学投资人 4600 万美元融资
- 任命弗雷德里克·贝丁菲尔德 (Frederick Beddingfield) 为首席执行官

日期 (2020 年 10 月 X 日) - 全球生物技术公司科越医药率先推出新一代治疗免疫介导疾病的补体靶向疗法，公司今天宣布，迄今为止已获得 4600 万美元投资并任命弗雷德里克·贝丁菲尔德医学博士 (Frederick Beddingfield, MD, PhD) 为首席执行官。科越医药由泉创资本 (Quan Capital)、6 Dimensions Capital、启明创投 (Qiming Venture Partners) 以及国药资本 (Sinopharm Capital) 等全球领先的生命科学风投公司联合提供支持，公司计划迅速推进一系列创新疗法，旨在实现更好、更持久的免疫调控。

“科越已开发出一款科学创新平台技术兼突破性方法，为补体介导疾病患者开发革新性疗法，”科越医药高级顾问、董事会成员兼科越主投资方泉创资本的风投合伙人彼得·沃斯 (Peter Wirth) 介绍道。“科越准备推进打造一根稳健的管道，把补体靶向疗法推广至临床，在这个至关重要的时刻，我们非常欢迎弗雷德里克加入科越。他在组建和指导科研组织方面具有丰富的经验和专业的知识，这对科越而言无比珍贵。”

“科越的创始团队已经开发出一个智能药物发现平台，用于推进开发能克服补体药物发现过程中各种挑战并且能够以慎密的创新方法调节补体系统的新型化合物，”科越医药首席执行官贝丁菲尔德博士说道。“能够加入科越，助力公司推进若干首创疗法，为急需治疗选择方案的患者送去福音，为此我倍感荣幸，也十分激动。”

科越计划在未来 18 个月把三种补体靶向疗法推广至临床，重点治疗炎症疾病、自身免疫性疫病和肿瘤。科越最先进的治疗方案是 P014，这是一款首创生物药物，具有独特的作用机制，旨在抑制上游和下游的补体靶点。P014 通过调节对疾病发展至关重要的补体活化级联中的两个单独的限速步骤，以此为补体抑制提供一种强有力且可能更加安全的治疗方法。P014 还设计有更长的半衰期和效力，从而让患者有可能在家中就实现自我管理。

科越医药由补体生物领域的几名顶级专家联合创立，公司已设计出自己的 LOGIC 药物发现平台 (先导物识别、优化和属体生成、体内确认)，用于克服补体药物发现过程中的各种挑战。在人类的许多疾病中，补体系统是炎症和组织损伤的一个关键驱动因素和放大器，但是，补体系统本身却很复杂，而且一向难以被靶向攻破。

“这个药物发现平台是基于宾夕法尼亚大学授权的技术和动物模型而创建的，我们将通过这个平台把我们的研究成果转化为药物，提供给急需的患者使用，为此我感到非常欣慰，”科越医药的科学联合创始人兼科学顾问委员会主席宋文超博士 (Wenchao Song,

PhD) 说道。同时, 宋博士也是宾夕法尼亚大学佩雷尔曼医学院系统药理学和转化治疗学教授。

贝丁菲尔德博士加入科越, 为公司带来近 20 年的生物制药经验。他将带领科越迅速扩大其 LOGIC 平台的影响力, 同时把一系列补体靶向疗法推广至临床。在此之前, 贝丁菲尔德博士是塞纳生物制药公司 (Sienna Biopharmaceuticals) 的创始人兼首席执行官, 该公司致力于开发炎症及免疫介导皮肤疾病的局部疗法和系统疗法。在创建塞纳 (Sienna) 之前, 他曾在 Kythera 生物制药公司和 Allergan Medical 生物制药公司担任首席医学官。贝丁菲尔德博士拥有皮肤病学、莫斯显微镜外科手术、皮肤肿瘤以及急诊医学领域的委员会认证, 同时也是加州大学洛杉矶分校 (UCLA) 的临床副教授。贝丁菲尔德博士在北卡罗来纳大学 (UNC) 教堂山分校获得医学博士学位, 在帕地兰德研究生院 (Pardee RAND Graduate School) 获得博士学位。

### 关于科越医药

科越医药是一家致力于开发治疗免疫介导疾病的补体靶向疗法的生物技术公司。公司凭借自己的 LOGIC 药物发现平台, 致力于推进首创疗法及一流的疗法, 以此彻底改善补体驱动型疾病患者的生活。科越医药在美国马萨诸塞州剑桥市设有多个办事处, 并且在中国苏州和上海设有研发中心, 以此致力于建立全球足迹, 在全球推广能够改善患者生活的疗法。

更多详情, 请访问网址 [www.kirapharma.com](http://www.kirapharma.com)。

### 编者按

宋文超博士 (Wenchao Song, PhD) 拥有科越医药的公司股权、从科越医药收取顾问费及研究经费, 同时也是科越医药专利许可的发明者之一, 并且, 宋文超博士可从公司成功研发的产品及产品商业化中获得经济收益。